Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Stephen MayoDirector | Sarepta TherapeuticsSRPT | Open-market sale | 03/12 | 03/13 | 7,239 sh | $17.02 | $123,207.78 | −80.4% |
Sarepta TherapeuticsSRPT | Open-market sale | 25/12/16 | 25/12/18 | 13,187 sh | $22.31 | $294,201.97 | −6.4% | |
Claude NicaiseDirector | Sarepta TherapeuticsSRPT | Open-market sale | 25/03/12 | 25/03/13 | 2,491 sh | $99.64 | $248,203.24 | −8.2% |
Hans Lennart Rudolf WigzellDirector | Sarepta TherapeuticsSRPT | Open-market sale | 24/12/12 | 24/12/16 | 10,500 sh | $124.84 | $1,310,820 | −31.5% |
Kathryn Jean BoorDirector | Sarepta TherapeuticsSRPT | Open-market sale | 24/12/05 | 24/12/06 | 1,636 sh | $125.55 | $205,399.8 | −21.8% |
Sarepta TherapeuticsSRPT | Open-market sale | 24/08/30 | 24/09/03 | 5,985 sh | $137.36 | $822,099.6 | −15.0% | |
Sarepta TherapeuticsSRPT | Open-market buy | 24/08/16 | 24/08/20 | 37,038 sh3 trades | $133.80avg. | $4,955,728.14 | +15.0% | |
Sarepta TherapeuticsSRPT | Open-market sale10b5-1 plan | 24/06/25 | 24/06/25 | 38,957 sh7 trades | $161.61avg. | $6,296,029.42 | −69.5% | |
Sarepta TherapeuticsSRPT | Open-market sale10b5-1 plan | 24/06/24–24/06/25 | 24/06/25 | 11,757 sh6 trades | $163.13avg. | $1,917,891.11 | −40.4% | |
Dallan MurrayChief Customer Officer | Sarepta TherapeuticsSRPT | Open-market sale10b5-1 plan | 24/05/02 | 24/05/06 | 3,635 sh | $140.00 | $508,900 | −16.7% |
Kathryn Jean BoorDirector | Sarepta TherapeuticsSRPT | Open-market sale | 24/03/11 | 24/03/11 | 761 sh | $122.93 | $93,549.73 | −9.2% |
Sarepta TherapeuticsSRPT | Open-market sale | 24/03/08 | 24/03/11 | 15,000 sh3 trades | $123.25avg. | $1,848,795.25 | −39.6% | |
Stephen MayoDirector | Sarepta TherapeuticsSRPT | Open-market sale | 24/03/05 | 24/03/06 | 3,135 sh | $122.96 | $385,479.6 | −32.1% |
Sarepta TherapeuticsSRPT | Open-market sale | 24/03/01 | 24/03/05 | 1,200 sh | $128.30 | $153,960 | −3.0% | |
Ryan Edward BrownEVP, General Counsel | Sarepta TherapeuticsSRPT | Open-market sale | 24/03/01 | 24/03/05 | 2,000 sh | $125.34 | $250,680 | −5.9% |
Sarepta TherapeuticsSRPT | Open-market sale | 24/03/01 | 24/03/05 | 2,000 sh2 trades | $128.84avg. | $257,676.41 | −6.9% | |
Sarepta TherapeuticsSRPT | Open-market buy | 23/11/03 | 23/11/06 | 25,225 sh4 trades | $79.36avg. | $2,001,799.89 | +6.9% | |
Sarepta TherapeuticsSRPT | Open-market buy | 23/11/03 | 23/11/06 | 50,000 sh2 trades | $78.81avg. | $3,940,500 | +55.6% | |
Sarepta TherapeuticsSRPT | Open-market buy | 23/08/14 | 23/08/15 | 9,979 sh2 trades | $109.47avg. | $1,092,429.41 | +4.2% | |
Michael Andrew ChambersDirector | Sarepta TherapeuticsSRPT | Open-market buy | 23/08/11 | 23/08/14 | 23,686 sh | $108.05 | $2,559,272.3 | +11.1% |
